March 2026 Research Update

This month, the clearest message was that modern ear surgery approaches often achieved a dry ear and better hearing, but they did not make cholesteatoma a "one-and-done" problem for everyone. Studies reported high rates of ear dryness after different operations, yet longer follow-up still showed that retraction pockets and residual or recurrent cholesteatoma can appear months to years later. For patients, this helps explain why follow-up after cholesteatoma surgery remains a major part of the overall care journey. [1] [2]

In a series of extensive cholesteatoma treated with canal wall-down surgery plus mastoid obliteration using S53P4 bioactive glass, most ears became dry, but retraction was still common and some ears developed retraction-pocket cholesteatoma or residual disease on follow-up imaging. Younger age and having had more previous surgeries were linked to higher chances of these later problems in that report, which fits with the idea that anatomy and prior operations can influence long-term results. This adds practical context to why some people need continued monitoring even when early healing looks good. [1]

Endoscopic approaches were also reported with strong short- to mid-term results in selected situations. Adults with chronically draining mastoid cavities after earlier radical mastoidectomy were reported to achieve a dry ear after endoscopic revision surgery, with hearing improvement and only a few temporary side effects described. A separate case series of isolated malleus cholesteatoma removed endoscopically reported closed eardrum repairs and improved hearing, with no recurrence detected during 24 months of checks. [2] [3]

Cholesteatoma also appeared as a risk marker when endoscopic ear surgery was used for chronic suppurative otitis media, where the presence of cholesteatoma was one of the factors linked with higher chances of surgical failure at 6 months. This does not mean endoscopic surgery is unsuitable, but it reinforces that cholesteatoma cases can behave differently than infection alone and may be harder to fully control. [4]

Quality of life was measured in a large Japanese study across multiple ear conditions, including cholesteatoma, and surgery was reported to improve postoperative quality of life. The study did not provide cholesteatoma-only numbers in the summary, but it supports the patient experience that ear disease can reduce day-to-day well-being and that surgery may improve it. This adds a broader view beyond hearing tests and ear dryness alone. [5]

For patients and caregivers, these studies mainly add clarity about what to expect from the overall course: many people heal to a dry ear and better hearing, but some still develop structural changes (like retraction pockets) or leftover or returning cholesteatoma that may only show up later. The evidence here comes from routine-care series and does not compare different surgeries head-to-head, so it cannot say which operation is best for an individual. What became clearer this month is that long-term outcomes depend on factors like age, prior surgeries, and whether cholesteatoma is present alongside other chronic ear disease, and that quality of life can improve after surgery even when follow-up remains important. [1] [2] [3] [4] [5]

Studies focused on how to detect cholesteatoma that comes back or was left behind, and they pointed in the same direction: detection often takes time and may need repeated checks. A meta-analysis across many studies suggested that routine diffusion-weighted MRI is more informative after the first year than in the very early months, and that surveillance may need to continue for several years because recurrences can be slow. In parallel, an exploratory lab study tested a rapid "tissue signature" approach that could potentially support surgeons in distinguishing cholesteatoma from nearby tissue, but it is not yet proven in real operations. [6] [7]

Across 16 studies, MRI positivity for postoperative cholesteatoma was reported at multiple time points, with notable rates still seen at 24 months and later. The authors interpreted this pattern as supporting a first routine scan at 12 to 24 months and then ongoing imaging if the first scan is negative, reflecting that recurrence or residual disease may not be detectable right away. The summary also reported differences by surgical approach in the included studies, with higher MRI positivity after canal wall-up surgery than after obliteration at some time points. [6]

In an ex vivo study using tissue samples removed during cholesteatoma surgery, a 405-nm autofluorescence spectroscopy system separated cholesteatoma from surrounding tissue with high reported accuracy and near-instant results. Because this was done on samples outside the body, it mainly shows technical promise rather than patient benefit today. It does, however, illustrate a possible future direction for more objective ways to recognize cholesteatoma tissue during surgery, if confirmed in living patients. [7]

For patients, this set of studies helps explain why follow-up imaging can be planned over a long time horizon after cholesteatoma surgery, since detection of residual or recurrent disease may be more likely after the first year and can still occur several years later. The MRI conclusions come from combining many studies, which strengthens the overall pattern but still leaves uncertainty about the best schedule for each person and each surgical approach. The spectroscopy work is early research and does not change current care, but it adds to the longer-term goal of making cholesteatoma identification more precise. [6] [7]

This month also expanded the picture beyond routine middle-ear cholesteatoma surgery. A very large health-record analysis found that people coded as having cholesteatoma were more likely to also have diagnoses of depressive disorders, suggesting that the burden of conductive hearing loss conditions can extend into mental health. Separately, a single case report described a rare cholesteatoma occurring inside the skull without ear disease, showing that the word "cholesteatoma" can also refer to uncommon situations outside typical ear symptoms. [8] [9]

In the All of Us cohort of adults, cholesteatoma was linked to higher odds of major depressive disorder and dysthymia compared with people without that diagnosis code. Because this was a cross-sectional study based on diagnosis codes, it cannot show whether cholesteatoma causes depression or explain the pathway, but it makes the overlap more visible at a population level. For patients, it is a reminder that ear disease can connect with mood and daily functioning in ways that may not be captured by ear exams alone. [8]

One report described a 29-year-old man with an intracranial cholesteatoma presenting as a posterior fossa mass and neurological symptoms, without ear disease. Imaging with diffusion-weighted MRI supported the diagnosis, surgery removed most of the mass, and the patient improved with no recurrence seen at 6 months. As a single case, it does not change expectations for typical ear cholesteatoma, but it documents how uncommon forms can be identified and followed. [9]

For patients and caregivers, the depression link is the more immediately relatable finding, because it suggests that cholesteatoma and similar hearing-related ear problems often coexist with diagnosed mood disorders in real-world data. This may matter now as a way of understanding the full burden of the condition, but it does not establish cause and effect. The intracranial case is mainly educational and rare, and it matters most as context for why imaging is sometimes important when symptoms do not fit typical ear disease. [8] [9]